BioSpace

Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again

Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by competitors.

By BioSpace

1 min read
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights